...
机译:早期转移性黑素瘤T-VEC的高反应率(阶段IIIB / C-IVM1A)
Department of Surgical OncologyThe Netherlands Cancer Institute‐Antoni van LeeuwenhoekAmsterdam The;
Department of Head and Neck Surgery and OncologyThe Netherlands Cancer Institute‐Antoni van;
Department of Head and Neck Surgery and OncologyThe Netherlands Cancer Institute‐Antoni van;
Departments of Nuclear MedicineThe Netherlands Cancer Institute‐Antoni van LeeuwenhoekAmsterdam The;
Department of PathologyThe Netherlands Cancer Institute‐Antoni van LeeuwenhoekAmsterdam The;
Department of Surgical OncologyThe Netherlands Cancer Institute‐Antoni van LeeuwenhoekAmsterdam The;
Department of Surgical OncologyThe Netherlands Cancer Institute‐Antoni van LeeuwenhoekAmsterdam The;
Department of Surgical OncologyThe Netherlands Cancer Institute‐Antoni van LeeuwenhoekAmsterdam The;
Department of Surgical OncologyThe Netherlands Cancer Institute‐Antoni van LeeuwenhoekAmsterdam The;
melanoma; oncolytic virus; immunotherapy; Talimogene Laherparepvec; T‐VEC; response evaluation;
机译:早期转移性黑素瘤T-VEC的高反应率(阶段IIIB / C-IVM1A)
机译:现实世界使用Talimogene Laherparepvec在德国IIIB阶段患者到IVM1A黑色素瘤:回顾性图表和医生调查
机译:talimogene laherparepvec与粒细胞-巨噬细胞集落刺激因子在IIIB / C期和IVM1a黑色素瘤患者中的疗效和安全性:OPTiM III期试验的亚分析
机译:阶段IIIB / Tier 4i和阶段IV / Tier 4发动机系统在农业拖拉机中集成
机译:预测转移性黑色素瘤中抗PD-1免疫疗法的反应。
机译:在Talimogene Laherparepvec(T-VEC)治疗的第三阶段OPTiM试验中未切除的IIIb-IV期黑色素瘤患者的持久反应(DR)与总体生存(OS)之间的关联
机译:在Talimogene Laherparepvec(T-VEC)治疗的第三阶段OPTiM试验中,未切除的IIIb-IV期黑色素瘤患者的持久反应(DR)与总体生存(OS)之间的关联